dose sales - sensitivity analysis

Several posters have addressed the Sp value to the dose sales growth.

We know the following:
that the elevated SP of high 30s was based on 20% dose growth for the next 4/5 years.
the SP was hammered twice on reduction of estimates dose growth.
guidance is expect to be single digits.
the good work from SLC regarding analysis on SP based on growth.

So, the Q is, has anyone done a sensitively analysis of US dose growth (the only game on town) for the current 6 months?

My view is that the US growth over the current 6 months has the largest impact on the SP in the immediate future.

Would be good is anyone can post the analysis for US dose growth at the following rates:
3%
4%
6%
8%
10%
12%
15%

I would do this but am flat out with EOY crap currently.
Cheers
CAFA